Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMCILL vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Infections of the respiratory tract,Infections of the genitourinary tract,Meningitis,Septicemia,Endocarditis,Gastrointestinal infections,Prophylaxis of bacterial endocarditis
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Partially metabolized by hydrolysis; primarily excreted unchanged in urine via renal tubular secretion and glomerular filtration.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: 60-80% unchanged; biliary: less than 10%; fecal: small amount.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
20% bound, primarily to albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.3 L/kg; indicates distribution into extracellular fluid.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 50-70% (variable, reduced by food); IM: nearly 100%.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For Cr Cl 30-50 m L/min: administer every 12 hours; for Cr Cl 10-29 m L/min: administer every 18-24 hours; for Cr Cl <10 m L/min: administer every 24 hours.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No specific adjustments recommended for Child-Pugh A or B; use caution in severe hepatic impairment (Child-Pugh C) with monitoring.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Children >1 month: 25-50 mg/kg/day orally divided every 8 hours; for severe infections, up to 100 mg/kg/day IV divided every 6 hours. Maximum dose: 2 g/day.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment required; monitor renal function and adjust based on creatinine clearance.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No FDA black box warning.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Hypersensitivity reactions including anaphylaxis,Clostridioides difficile-associated diarrhea,Superinfection,Risk of seizures with high doses or renal impairment,Use caution in patients with mononucleosis (high risk of rash)
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to ampicillin, penicillins, or any component of the formulation,Infections caused by beta-lactamase-producing organisms
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Food does not significantly affect absorption; may be taken with or without meals. Avoid alcohol: may increase risk of disulfiram-like reaction (rare).
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearly needed; potential for altered gut flora and diarrhea in neonate.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Ampicillin is excreted in breast milk in low concentrations (M/P ratio approximately 0.2). Compatible with breastfeeding; monitor infant for diarrhea or rash.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Increased renal clearance during pregnancy may require higher doses to maintain therapeutic levels. Standard dosing is usually adequate for most indications; consider monitoring serum levels in severe infections.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
AMCILL (ampicillin) is a broad-spectrum penicillinase-sensitive penicillin. Use caution in patients with renal impairment; dose adjustment required for Cr Cl <30 m L/min. Monitor for hypersensitivity reactions, especially in patients with cephalosporin allergy. IV administration may cause phlebitis; rotate infusion sites. Not effective against penicillinase-producing organisms including Staphylococcus aureus.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed; complete full course even if you feel better.,Notify your doctor if you develop rash, hives, or difficulty breathing.,May cause diarrhea; contact your doctor if severe or bloody.,Take with a full glass of water; avoid acidic beverages like orange juice.,Inform your doctor if you are pregnant, breastfeeding, or taking oral contraceptives (ampicillin may reduce efficacy).
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMCILL vs ABSTRAL, answered by our medical review team.
AMCILL is a Penicillin Antibiotic that works by Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMCILL and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMCILL is: 250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMCILL and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMCILL is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearl. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.